Breaking News

Quotient Clinical Begins 50th RapidFACT Program

By Kristin Brooks | February 6, 2014

Translational platform incorporates real-time GMP manufacturing and clinical testing

Quotient Clinical, a translational pharmaceutics company, began its 50th RapidFACT (Rapid Formulation development And Clinical Testing) program. RapidFACT was developed in 2008 with the goal of transforming the process of optimizing drug product formulations. According to the company, this service has now been proven to accelerate program timelines by at least 50% and reduce costs. Quotient’s translational pharmaceutics platform incorporates realtime GMP manufacturing and clinical testing, which enables formulation selection to be supported by emerging clinical data.
 
RapidFACT has been deployed in early development and life cycle management programs to develop oral, inhaled, dermal and ocular drug products. These programs have focused on optimizing drug products for once- or twice-daily dosing, or addressing poor solubility. 
 
Mark Egerton, chief executive officer of Quotient Clinical, said, "RapidFACT was launched in response to the challenges our customers told us they were confronting in their development programs.  We are pleased that the potential benefits we identified in 2008 have translated into real timeline reductions and cost savings in all of our RapidFACT programs. Ultimately, this approach is helping our customers to address many of the R&D productivity issues prevalent in the industry today."

blog comments powered by Disqus
  • Top 25 Pharma and Biopharma Report

    Top 25 Pharma and Biopharma Report

    July 20, 2015
    (Based on 2014 Sales, in $U.S. Millions)

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important